Jeffrey Dunn Sells 80,000 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) Director Jeffrey Dunn sold 80,000 shares of the stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $18.95, for a total transaction of $1,516,000.00. Following the completion of the transaction, the director owned 10,307 shares of the company’s stock, valued at $195,317.65. This represents a 88.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

SiBone Stock Up 0.9%

SIBN stock opened at $17.42 on Friday. The company has a current ratio of 7.97, a quick ratio of 7.00 and a debt-to-equity ratio of 0.21. The company’s 50-day moving average price is $15.32 and its 200 day moving average price is $16.62. SiBone has a 52 week low of $11.70 and a 52 week high of $20.05. The company has a market cap of $755.85 million, a P/E ratio of -34.16 and a beta of 0.81.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The company had revenue of $48.66 million during the quarter, compared to the consensus estimate of $46.67 million. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. SiBone has set its FY 2025 guidance at EPS. On average, research analysts expect that SiBone will post -0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. American Century Companies Inc. grew its holdings in shares of SiBone by 22.5% during the third quarter. American Century Companies Inc. now owns 2,838,107 shares of the company’s stock worth $41,777,000 after buying an additional 521,683 shares in the last quarter. Vanguard Group Inc. grew its stake in SiBone by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,489,989 shares of the company’s stock worth $36,653,000 after acquiring an additional 41,449 shares during the period. First Light Asset Management LLC raised its holdings in SiBone by 8.6% in the 2nd quarter. First Light Asset Management LLC now owns 1,751,001 shares of the company’s stock valued at $32,954,000 after acquiring an additional 138,593 shares during the last quarter. Nuveen LLC purchased a new position in shares of SiBone during the 1st quarter worth $18,605,000. Finally, Impax Asset Management Group plc lifted its stake in shares of SiBone by 48.2% during the 3rd quarter. Impax Asset Management Group plc now owns 1,025,010 shares of the company’s stock worth $15,088,000 after purchasing an additional 333,249 shares during the period. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SIBN. Truist Financial lowered their target price on SiBone from $22.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, October 15th. Cantor Fitzgerald set a $25.00 price objective on shares of SiBone and gave the company an “overweight” rating in a research note on Monday, August 11th. Weiss Ratings restated a “sell (d-)” rating on shares of SiBone in a research report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, SiBone presently has an average rating of “Moderate Buy” and a consensus price target of $23.00.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.